Evaluation of modification of diet in renal disease study and cockcroft-gault equations for sitagliptin dosing

Joanna Laizure, M. Shawn Mcfarland, Brandon M. Markley, Ping Zhang

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Assessment of kidney function is necessary to determine appropriate dosing regimens. While the Cockcroft-Gault (CG) equation is used to calculate the estimated creatinine clearance (eCLCr) for drug dosing, the Modification of Diet in Renal Disease (MDRD) Study equation has recently been advocated. Sitagliptin is a dipeptidyl-peptidase IV inhibitor with dose adjustments based on eCLCr. We assessed discordance in sitagliptin doses recommended using MDRD and CG equations. Methods: Adult patients with type 2 diabetes mellitus were included. Estimated glomerular filtration rate (eGFR) individualized for body surface area (eGFR-BSA) and eCLCr were calculated by the MDRD and CG equations, respectively, and sitagliptin dose was determined. Discordance in doses recommended by method were compared overall and by subgroup based on eCLCr category. Results: A total of 121 patients were included: 52% male, 90% white, mean age 61 ± 12 years, weight 93 ± 19 kg, BSA 2.0 ± 0.22 m 2 and body mass index (BMI; calculated as kg/m 2) 33 ± 7. Mean eGFR-BSA was 76 ± 19 ml/min and eCLCr was 68 ± 17 ml/min. Discordance in sitagliptin dose was observed in 11 patients (9%) with MDRD compared with CG. All patients with eCLCr ≤50 would have received a higher dose using MDRD, while patients with eCLCr >50 would have received a lower dose.Conclusions: Overall there was agreement in sita-gliptin dose using MDRD and CG equations. Discrepancies resulted in underestimation of sitagliptin dose at eCLCr above 50 ml/min and overestimation at lower eCLCr. Clinical implications are the potential for excessive dosing of sitagliptin and other agents with similar dose stratification by eCLCr in individuals with kidney dysfunction.

Original languageEnglish (US)
Pages (from-to)515-522
Number of pages8
JournalJournal of Nephrology
Volume25
Issue number4
DOIs
StatePublished - Jul 1 2012

Fingerprint

Diet Therapy
Kidney
Dipeptidyl-Peptidase IV Inhibitors
Glomerular Filtration Rate
Sitagliptin Phosphate
Body Surface Area
Type 2 Diabetes Mellitus
Creatinine
Body Mass Index
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Evaluation of modification of diet in renal disease study and cockcroft-gault equations for sitagliptin dosing. / Laizure, Joanna; Mcfarland, M. Shawn; Markley, Brandon M.; Zhang, Ping.

In: Journal of Nephrology, Vol. 25, No. 4, 01.07.2012, p. 515-522.

Research output: Contribution to journalArticle

Laizure, Joanna ; Mcfarland, M. Shawn ; Markley, Brandon M. ; Zhang, Ping. / Evaluation of modification of diet in renal disease study and cockcroft-gault equations for sitagliptin dosing. In: Journal of Nephrology. 2012 ; Vol. 25, No. 4. pp. 515-522.
@article{25bc0204d5a84af5a8ad7b3f9168bafc,
title = "Evaluation of modification of diet in renal disease study and cockcroft-gault equations for sitagliptin dosing",
abstract = "Background: Assessment of kidney function is necessary to determine appropriate dosing regimens. While the Cockcroft-Gault (CG) equation is used to calculate the estimated creatinine clearance (eCLCr) for drug dosing, the Modification of Diet in Renal Disease (MDRD) Study equation has recently been advocated. Sitagliptin is a dipeptidyl-peptidase IV inhibitor with dose adjustments based on eCLCr. We assessed discordance in sitagliptin doses recommended using MDRD and CG equations. Methods: Adult patients with type 2 diabetes mellitus were included. Estimated glomerular filtration rate (eGFR) individualized for body surface area (eGFR-BSA) and eCLCr were calculated by the MDRD and CG equations, respectively, and sitagliptin dose was determined. Discordance in doses recommended by method were compared overall and by subgroup based on eCLCr category. Results: A total of 121 patients were included: 52{\%} male, 90{\%} white, mean age 61 ± 12 years, weight 93 ± 19 kg, BSA 2.0 ± 0.22 m 2 and body mass index (BMI; calculated as kg/m 2) 33 ± 7. Mean eGFR-BSA was 76 ± 19 ml/min and eCLCr was 68 ± 17 ml/min. Discordance in sitagliptin dose was observed in 11 patients (9{\%}) with MDRD compared with CG. All patients with eCLCr ≤50 would have received a higher dose using MDRD, while patients with eCLCr >50 would have received a lower dose.Conclusions: Overall there was agreement in sita-gliptin dose using MDRD and CG equations. Discrepancies resulted in underestimation of sitagliptin dose at eCLCr above 50 ml/min and overestimation at lower eCLCr. Clinical implications are the potential for excessive dosing of sitagliptin and other agents with similar dose stratification by eCLCr in individuals with kidney dysfunction.",
author = "Joanna Laizure and Mcfarland, {M. Shawn} and Markley, {Brandon M.} and Ping Zhang",
year = "2012",
month = "7",
day = "1",
doi = "10.5301/jn.5000026",
language = "English (US)",
volume = "25",
pages = "515--522",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Wichtig Publishing",
number = "4",

}

TY - JOUR

T1 - Evaluation of modification of diet in renal disease study and cockcroft-gault equations for sitagliptin dosing

AU - Laizure, Joanna

AU - Mcfarland, M. Shawn

AU - Markley, Brandon M.

AU - Zhang, Ping

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Background: Assessment of kidney function is necessary to determine appropriate dosing regimens. While the Cockcroft-Gault (CG) equation is used to calculate the estimated creatinine clearance (eCLCr) for drug dosing, the Modification of Diet in Renal Disease (MDRD) Study equation has recently been advocated. Sitagliptin is a dipeptidyl-peptidase IV inhibitor with dose adjustments based on eCLCr. We assessed discordance in sitagliptin doses recommended using MDRD and CG equations. Methods: Adult patients with type 2 diabetes mellitus were included. Estimated glomerular filtration rate (eGFR) individualized for body surface area (eGFR-BSA) and eCLCr were calculated by the MDRD and CG equations, respectively, and sitagliptin dose was determined. Discordance in doses recommended by method were compared overall and by subgroup based on eCLCr category. Results: A total of 121 patients were included: 52% male, 90% white, mean age 61 ± 12 years, weight 93 ± 19 kg, BSA 2.0 ± 0.22 m 2 and body mass index (BMI; calculated as kg/m 2) 33 ± 7. Mean eGFR-BSA was 76 ± 19 ml/min and eCLCr was 68 ± 17 ml/min. Discordance in sitagliptin dose was observed in 11 patients (9%) with MDRD compared with CG. All patients with eCLCr ≤50 would have received a higher dose using MDRD, while patients with eCLCr >50 would have received a lower dose.Conclusions: Overall there was agreement in sita-gliptin dose using MDRD and CG equations. Discrepancies resulted in underestimation of sitagliptin dose at eCLCr above 50 ml/min and overestimation at lower eCLCr. Clinical implications are the potential for excessive dosing of sitagliptin and other agents with similar dose stratification by eCLCr in individuals with kidney dysfunction.

AB - Background: Assessment of kidney function is necessary to determine appropriate dosing regimens. While the Cockcroft-Gault (CG) equation is used to calculate the estimated creatinine clearance (eCLCr) for drug dosing, the Modification of Diet in Renal Disease (MDRD) Study equation has recently been advocated. Sitagliptin is a dipeptidyl-peptidase IV inhibitor with dose adjustments based on eCLCr. We assessed discordance in sitagliptin doses recommended using MDRD and CG equations. Methods: Adult patients with type 2 diabetes mellitus were included. Estimated glomerular filtration rate (eGFR) individualized for body surface area (eGFR-BSA) and eCLCr were calculated by the MDRD and CG equations, respectively, and sitagliptin dose was determined. Discordance in doses recommended by method were compared overall and by subgroup based on eCLCr category. Results: A total of 121 patients were included: 52% male, 90% white, mean age 61 ± 12 years, weight 93 ± 19 kg, BSA 2.0 ± 0.22 m 2 and body mass index (BMI; calculated as kg/m 2) 33 ± 7. Mean eGFR-BSA was 76 ± 19 ml/min and eCLCr was 68 ± 17 ml/min. Discordance in sitagliptin dose was observed in 11 patients (9%) with MDRD compared with CG. All patients with eCLCr ≤50 would have received a higher dose using MDRD, while patients with eCLCr >50 would have received a lower dose.Conclusions: Overall there was agreement in sita-gliptin dose using MDRD and CG equations. Discrepancies resulted in underestimation of sitagliptin dose at eCLCr above 50 ml/min and overestimation at lower eCLCr. Clinical implications are the potential for excessive dosing of sitagliptin and other agents with similar dose stratification by eCLCr in individuals with kidney dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=84863946836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863946836&partnerID=8YFLogxK

U2 - 10.5301/jn.5000026

DO - 10.5301/jn.5000026

M3 - Article

VL - 25

SP - 515

EP - 522

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 4

ER -